Phase I/Ib Trial of Radiotherapy in Combination With Durvalumab (MEDI4736) Prior to Surgical Resection for HPV Negative Squamous Cell Carcinoma of the Head and Neck (HNSCC)
Phase of Trial: Phase I
Latest Information Update: 06 Sep 2019
Price : $35 *
At a glance
- Drugs Durvalumab (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Adverse reactions
- 02 Nov 2018 Status changed from not yet recruiting to recruiting.
- 09 Oct 2018 Planned initiation date changed from 1 Sep 2018 to 1 Dec 2018.
- 24 Aug 2018 New trial record